Brief: Novozymes A/S Says Novonesis Expects 6-9% Sales Cagr, 39% EBITDA Margin By 2030

Novozymes A/S

20/08/2025 16:52

Aug 20 (Reuters) - Novozymes A/S NSISb.CO:

NOVOZYMES A/S - NOVONESIS EXPECTS 6-9% SALES CAGR, 39% EBITDA MARGIN BY 2030

Source text: ID:nGNE7NBfvD

Further company coverage: [NSISb.CO]

 ((Reuters.Briefs@thomsonreuters.com;))